Last 47 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Gilead Sciences, Inc.'s quarterly P/E stands at 17.6x, up 8.4% year-over-year. EV/EBITDA has expanded 55.1% YoY to 16.5x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 358.68 | 17.64 | 11.42 | 17.77 | 26.94 | 16.26 | 20.96 | 13.30 | — | 17.77 | 10.83 | 23.21 | 25.93 |
| — | +8.4% | -45.5% | +33.6% | — | -8.5% | +93.5% | -42.7% | — | +7.6% | -0.3% | +36.7% | -98.3% | |
| P/S Ratio | 5.91 | 4.85 | 4.48 | 4.91 | 5.29 | 3.84 | 3.48 | 3.09 | 3.42 | 3.58 | 3.34 | 3.67 | 4.12 |
| — | +26.3% | +28.6% | +59.2% | +54.9% | +7.4% | +4.3% | -16.0% | -17.1% | -2.6% | +21.0% | +18.1% | +44.7% | |
| P/B Ratio | 8.89 | 6.80 | 6.49 | 7.10 | 7.39 | 6.04 | 5.72 | 4.72 | 5.23 | 4.47 | 4.24 | 4.60 | 5.00 |
| — | +12.5% | +13.5% | +50.6% | +41.3% | +35.1% | +35.0% | +2.6% | +4.7% | -12.6% | +14.6% | +19.3% | +32.6% | |
| P/FCF | 16.48 | 11.56 | 8.79 | 48.31 | 21.34 | 10.28 | 6.31 | 17.96 | 10.80 | 13.02 | 14.42 | 11.02 | 16.00 |
| — | +12.4% | +39.3% | +169.1% | +97.5% | -21.0% | -56.3% | +62.9% | -32.5% | +14.5% | +100.7% | -6.1% | +35.9% | |
| EV / EBITDA | 42.12 | 16.47 | 9.77 | 12.55 | 13.48 | 10.62 | 19.54 | 7.97 | — | 13.19 | 8.58 | 12.41 | 13.32 |
| — | +55.1% | -50.0% | +57.5% | — | -19.5% | +127.8% | -35.8% | — | +14.9% | +17.3% | +27.6% | -60.3% | |
| EV / EBIT | 112.24 | 16.47 | 10.06 | 14.81 | 20.70 | 13.83 | 25.83 | 11.62 | — | 15.92 | 11.13 | 16.02 | 20.41 |
| — | +19.1% | -61.1% | +27.5% | — | -13.2% | +132.1% | -27.5% | — | +12.0% | +20.4% | +12.5% | -92.8% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Gilead Sciences, Inc.'s operating margin was 37.4% in Q4 2025, down 5.4 pp QoQ and up 5.0 pp YoY. Gross margin expanded 9.8% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.3% | 86.8% | 79.8% | 78.8% | 76.9% | 79.1% | 79.1% | 77.8% | 76.8% | 70.6% | 77.8% | 78.1% | 77.9% |
| — | +9.8% | +0.8% | +1.3% | +0.1% | +12.0% | +1.7% | -0.5% | -1.5% | -12.9% | -3.0% | +1.5% | -0.6% | |
| Operating Margin | 5.8% | 37.4% | 42.8% | 34.9% | 33.6% | 32.4% | 11.8% | 38.0% | -64.6% | 22.7% | 37.2% | 25.2% | 26.8% |
| — | +15.5% | +263.9% | -8.1% | +151.9% | +43.0% | -68.4% | +50.7% | -340.8% | -26.1% | -7.6% | -22.2% | +797.9% | |
| Net Margin | 1.7% | 27.5% | 39.3% | 27.7% | 19.7% | 23.6% | 16.6% | 23.2% | -62.4% | 20.1% | 30.9% | 15.8% | 15.9% |
| — | +16.9% | +136.6% | +19.2% | +131.6% | +17.3% | -46.3% | +46.6% | -492.2% | -9.5% | +21.7% | -13.3% | +5415.3% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 2.3% | 9.9% | 14.9% | 10.1% | 6.9% | 9.5% | 6.8% | 9.1% | -20.7% | 6.4% | 10.1% | 5.0% | 4.8% |
| — | +4.5% | +117.1% | +12.0% | +133.1% | +49.2% | -31.9% | +82.1% | -532.8% | -18.1% | +16.1% | -12.8% | +5070.0% | |
| ROA | 0.8% | 3.7% | 5.3% | 3.5% | 2.3% | 3.1% | 2.3% | 2.9% | -7.0% | 2.3% | 3.5% | 1.7% | 1.6% |
| — | +18.2% | +130.5% | +19.0% | +132.4% | +36.8% | -33.7% | +74.6% | -536.0% | -12.0% | +22.6% | -7.4% | +5470.3% | |
| ROIC | 3.2% | 7.2% | 6.4% | 4.9% | 4.6% | 5.0% | 1.8% | 5.2% | -8.1% | 2.9% | 4.8% | 3.1% | 3.1% |
| — | +43.4% | +259.9% | -4.9% | +157.2% | +74.3% | -63.1% | +69.5% | -359.9% | -29.9% | -6.3% | -16.3% | +786.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 5.4% YoY to 1.68x, strengthening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.39 | — | 1.16 | 1.27 | 1.31 | 1.42 | 1.26 | 1.28 | 1.44 | 1.13 | 1.12 | 1.20 | 1.21 |
| — | — | -8.1% | -0.8% | -9.4% | +25.9% | +12.6% | +7.2% | +19.7% | -5.2% | -6.2% | -7.7% | -8.4% | |
| Debt / EBITDA | 6.03 | — | 6.22 | 7.88 | 8.51 | 8.69 | 14.73 | 7.00 | — | 11.16 | 7.55 | 10.76 | 10.76 |
| — | — | -57.8% | +12.7% | — | -22.1% | +95.0% | -35.0% | — | +23.6% | +0.7% | +4.8% | -70.3% | |
| Current Ratio | 1.60 | 1.68 | 1.45 | 1.32 | 1.37 | 1.60 | 1.26 | 1.14 | 1.08 | 1.43 | 1.34 | 1.02 | 1.28 |
| — | +5.4% | +15.3% | +15.1% | +26.9% | +12.0% | -5.8% | +11.7% | -15.6% | +11.0% | +2.9% | -28.4% | -13.4% | |
| Quick Ratio | 1.45 | 1.31 | 1.31 | 1.15 | 1.23 | 1.45 | 1.10 | 0.95 | 0.94 | 1.27 | 1.20 | 0.91 | 1.13 |
| — | -9.7% | +18.8% | +20.7% | +31.0% | +14.8% | -8.1% | +5.3% | -17.0% | +10.1% | +3.3% | -28.5% | -13.4% | |
| Interest Coverage | 1.70 | 11.62 | 13.00 | 9.74 | 8.60 | 9.85 | 3.73 | 11.16 | -17.02 | 6.40 | 11.31 | 7.24 | 7.41 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying GILD stock.
Gilead Sciences, Inc.'s current P/E is 358.7x. The average P/E over the last 4 quarters is 18.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Gilead Sciences, Inc.'s current operating margin is 5.8%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Gilead Sciences, Inc.'s business trajectory between earnings reports.